Open an account

Amneal Pharmaceuticals

AMRX · NASDAQ

$19.84+$0.48 (+2.48%)TodayMarket closed ·
Prev close $19.36

About AMRX

Amneal Pharmaceuticals, Inc. is a medicine company, which engages in the provision of pharmaceuticals. The company is headquartered in Bridgewater, New Jersey and currently employs 8,500 full-time employees. The company went IPO on 2009-11-18. Its Affordable Medicines segment includes a portfolio of over 280 product families covering a range of dosage forms and delivery systems, including both immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmic, films, transdermal patches and topicals. Its Specialty segment is engaged in the development, promotion, sale and distribution of branded pharmaceutical products, with a focus on products addressing central nervous system disorders, including Parkinson’s disease and endocrine disorders. Its AvKARE segment provides pharmaceuticals, medical and surgical products and services primarily to governmental agencies, predominantly focused on the U.S. Department of Defense and the U.S. Department of Veterans Affairs.

Employees
8,500
Headquarters
Bridgewater, New Jersey
Listed
Nov 18, 2009
Sector
Health Care
Industry
Pharmaceuticals
Website
amneal.com

AMRX key statistics

Market cap
6.34B
Price-earnings ratio
39.51
Dividend yield
—
Average volume
3.51M
Volume
6.82M
Open price
$19.51
High today
$19.91
Low today
$19.31
52 Week high
$21.18
52 Week low
$9.92

Amneal Pharmaceuticals (AMRX) at a glance

As of Oct 20, 2026, Amneal Pharmaceuticals (AMRX) shares are priced at $19.84, giving the company a market cap of 6.34B and a price-to-earnings ratio of 39.51.

Today the stock has traded between $19.31 and $19.91. The current price is 2.7% above the day's low and 0.4% below its high.

Volume so far is 6.82M shares, above the average of 3.51M shares a day.

Over the past year Amneal Pharmaceuticals has ranged from $9.92 to $21.18, and now sits 88% of the way up that range.

Amneal Pharmaceuticals met or beat analyst EPS estimates in 7 of the last 8 quarters. In Q2 FY26 it reported $0.30 per share against an estimate of $0.2259.

The average analyst price target is $22.76, 14.7% above the current price, from 6 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 6 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 9 analystsAvg $22.76
Low
$19.41
Now
$19.84
High
$28.35

AMRX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 7 of the last 8 quarters, by 31.1% on average.

  1. Q3 FY24: reported $0.16 per share against an estimate of $0.1377
  2. Q4 FY24: reported $0.12 per share against an estimate of $0.1556
  3. Q1 FY25: reported $0.21 per share against an estimate of $0.1496
  4. Q2 FY25: reported $0.25 per share against an estimate of $0.1785
  5. Q3 FY25: reported $0.17 per share against an estimate of $0.1403
  6. Q4 FY25: reported $0.21 per share against an estimate of $0.1883
  7. Q1 FY26: reported $0.27 per share against an estimate of $0.1734
  8. Q2 FY26: reported $0.30 per share against an estimate of $0.2259

AMRX news

  • Press releaseBusiness Wire

    STOCK ALERT: Kaskela Law Announces Shareholder Investigation of Amneal Pharmaceuticals, Inc. (AMRX) and Encourages Current AMRX Stockholders to Contact the Firm

  • Stjepan Kalinic

    Two Years to Build or Pay 200% — Which US Pharma Stocks Win?

  • Press releaseBusiness Wire

    Kaskela Law LLC Announces Investigation of Amneal Pharmaceuticals, Inc. (AMRX) and Encourages AMRX Shareholders to Contact the Firm

  • Vandana Singh

    Eli Lilly, Regeneron Join FDA Pilot Designed To Accelerate US Manufacturing Readiness

  • FDA Broadens Access to Over-The-Counter Naloxone Nasal Spray for Opioid Overdose

  • Press releasePRNewswire

    Dispensary of Hope Launches "Hope Alliance" Campaign with Support from Amneal Pharmaceuticals

  • Press releaseBusiness Wire

    Kashiv BioSciences Agrees to Be Acquired by Amneal Pharmaceuticals to Create a Fully Integrated Global Biosimilar Leader

  • FDA Takes Step Forward on Testosterone Therapy for Men

Similar companies

Companies in the same industry as Amneal Pharmaceuticals

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.